Robin Martin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Robin Martin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alan Graham Stuart
Bristol Medical School, University of Bristol, Bristol, United Kingdom
1 shared publication Amy Chambers
Bristol Congenital Heart Centre , Bristol Royal Hospital for Children and Bristol Royal Infirmary , Upper Maudlin Street, Bristol BS2 8BJ , UK
1 shared publicationAruna Ranasinghe
Bristol Congenital Heart Centre , Bristol Royal Hospital for Children and Bristol Royal Infirmary , Upper Maudlin Street, Bristol BS2 8BJ , UK
1 shared publicationCarlos C.A. Pedra
Instituto Dante Pazzanese de Cardiologia, Sao Paolo, Brazil (C.C.A.P.).
1 shared publication- Damien Kenny
Our Lady's Children's Hospital Crumlin Dublin Ireland
1 shared publication - David James
Southwest Pathology Service, Lisieux Way, Taunton TA1 2LB, UK
1 shared publication
Latest Publications
- 1 December 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 14 (12) , e010576
Large Diameter Advanta V12 Covered Stent Trial for Coarctation of the Aorta: COARC Study
Background: Covered stent implantation for treatment of coarctation of the aorta (CoA) is effective and can prevent aortic wall injury. Prospective studies with long-term follow-up, including imaging, are lacking. We report the acute and long-term outcomes for use of the Large Diameter Advanta V12 covered stent for treatment of native and recurrent CoA. Methods: A prospective, multicenter, nonrandomized study was performed including 70 patients (43 male), median age 17 years, median weight 57.4 kg with CoA who underwent implantation of the Large Diameter Advanta V12 covered stent. Annual follow-up for 5 years included Doppler echocardiography to calculate diastolic velocity: systolic velocity ratio. Results: CoA diameter increased from 5.6±3.6 to 14.9±3.9 mm ( P P P <0.0001) and was maintained at 5 years. Computed tomography angiograms at 12 months postimplantation demonstrated the stent:transverse arch diameter to be similar, 0.91±0.09 to postprocedure 0.86±0.14. Major adverse vascular events at 30 days and 12 months were 1.4% and 4.3%, respectively. Significant adverse events included three patients who required stent implantation to treat infolding. There were no mortalities. Conclusions: The Large Diameter Advanta V12 covered stent is safe and effective for the treatment of CoA with an immediate and sustained reduction of the pressure gradient over 12 months and 5 years as assessed by preimplantation and postimplantation Doppler echocardiography and 12-month computed tomography angiography. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00978952. URL: http://www.anzctr.org.au ; Unique identifier: ACTRN12612000013864.
- 1 December 2021
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 14 (12) , e010576
Large Diameter Advanta V12 Covered Stent Trial for Coarctation of the Aorta: COARC Study
Background: Covered stent implantation for treatment of coarctation of the aorta (CoA) is effective and can prevent aortic wall injury. Prospective studies with long-term follow-up, including imaging, are lacking. We report the acute and long-term outcomes for use of the Large Diameter Advanta V12 covered stent for treatment of native and recurrent CoA. Methods: A prospective, multicenter, nonrandomized study was performed including 70 patients (43 male), median age 17 years, median weight 57.4 kg with CoA who underwent implantation of the Large Diameter Advanta V12 covered stent. Annual follow-up for 5 years included Doppler echocardiography to calculate diastolic velocity: systolic velocity ratio. Results: CoA diameter increased from 5.6±3.6 to 14.9±3.9 mm ( P P P <0.0001) and was maintained at 5 years. Computed tomography angiograms at 12 months postimplantation demonstrated the stent:transverse arch diameter to be similar, 0.91±0.09 to postprocedure 0.86±0.14. Major adverse vascular events at 30 days and 12 months were 1.4% and 4.3%, respectively. Significant adverse events included three patients who required stent implantation to treat infolding. There were no mortalities. Conclusions: The Large Diameter Advanta V12 covered stent is safe and effective for the treatment of CoA with an immediate and sustained reduction of the pressure gradient over 12 months and 5 years as assessed by preimplantation and postimplantation Doppler echocardiography and 12-month computed tomography angiography. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00978952. URL: http://www.anzctr.org.au ; Unique identifier: ACTRN12612000013864.
- Open Access
- 18 January 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (3) , 303-307
Single-centre use of implantable loop recorders in patients with congenital heart disease
To determine the efficacy of the implantable loop recorder (ILR) in patients with congenital heart disease. Retrospective data analyses of all patients with congenital heart disease undergoing ILR implantation in a congenital cardiac centre. Of 78 ILRs implanted between July 2000 and October 2007, 22 (15 male) patients had congenital heart disease. The median age at implantation was 15.5 years (7.0–46.5). Six patients had neurodevelopmental delay. Indications for implantation were syncope ( n = 15), palpitations ( n = 4), and pre-syncope ( n = 3). Median implantation time was 19 months (1–30). Explantation data were available in 16 patients (73%). Implantable loop recorders were explanted following establishment of positive diagnosis ( n = 3), negative diagnosis ( n = 7), and at the end of battery life ( n = 4). One patient died with the ILR in situ . One device eroded after 2 months without further complication. Following ILR interrogation, diagnosed arrhythmias included ventricular tachycardia ( n = 2) and sinus node dysfunction ( n = 1). On the basis of these findings, two patients had intracardiac defibrillators and one patient had a dual-chamber pacemaker implanted. Implantable loop recorders lead to a positive or negative arrhythmic diagnosis following explantation in 71% of patients with congenital heart disease. This is particularly beneficial in patients with neurodevelopmental delay where accurate history is often limited.
- 18 January 2009
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 11 (3) , 303-307
Open AccessSingle-centre use of implantable loop recorders in patients with congenital heart disease
To determine the efficacy of the implantable loop recorder (ILR) in patients with congenital heart disease. Retrospective data analyses of all patients with congenital heart disease undergoing ILR implantation in a congenital cardiac centre. Of 78 ILRs implanted between July 2000 and October 2007, 22 (15 male) patients had congenital heart disease. The median age at implantation was 15.5 years (7.0–46.5). Six patients had neurodevelopmental delay. Indications for implantation were syncope ( n = 15), palpitations ( n = 4), and pre-syncope ( n = 3). Median implantation time was 19 months (1–30). Explantation data were available in 16 patients (73%). Implantable loop recorders were explanted following establishment of positive diagnosis ( n = 3), negative diagnosis ( n = 7), and at the end of battery life ( n = 4). One patient died with the ILR in situ . One device eroded after 2 months without further complication. Following ILR interrogation, diagnosed arrhythmias included ventricular tachycardia ( n = 2) and sinus node dysfunction ( n = 1). On the basis of these findings, two patients had intracardiac defibrillators and one patient had a dual-chamber pacemaker implanted. Implantable loop recorders lead to a positive or negative arrhythmic diagnosis following explantation in 71% of patients with congenital heart disease. This is particularly beneficial in patients with neurodevelopmental delay where accurate history is often limited.
- Open Access
- 1 October 1991
- Published by BMJ in Archives of Disease in Childhood
- Vol. 66 (10 Spec No) , 1160-1161
Intermittent fetal tachycardia and fetal hydrops.
A case is reported where fetal hydrops was noted 10 days after an initial observation of intermittent fetal tachycardia at 31 weeks. A diagnosis of supraventricular tachycardia was made and a successful conversion to sinus rhythm was achieved with maternally administered flecainide, with subsequent resolution of the hydrops. The fetus required no further treatment in pregnancy or at follow up. The mother suffered no side effects of the treatment.
- 1 October 1991
- Published by BMJ in Archives of Disease in Childhood
- Vol. 66 (10 Spec No) , 1160-1161
Open AccessIntermittent fetal tachycardia and fetal hydrops.
A case is reported where fetal hydrops was noted 10 days after an initial observation of intermittent fetal tachycardia at 31 weeks. A diagnosis of supraventricular tachycardia was made and a successful conversion to sinus rhythm was achieved with maternally administered flecainide, with subsequent resolution of the hydrops. The fetus required no further treatment in pregnancy or at follow up. The mother suffered no side effects of the treatment.